Diverse psychotropic substances detected in drug and drug administration equipment samples submitted to drug checking services in Toronto, Ontario, Canada, October 2019–April 2020

Kristy M. Scarfone1,2, Nazlee Maghsoudi1,3, Karen McDonald1, Cristiana Stefan4, Daniel R. Beriault5,6, Ernest Wong4, Mark Evert5, Shaun Hopkins7, Peter Leslie8, Tara Marie Watson9, Dan Werb1,3,10* and Toronto’s Drug Checking Service Working Group

Abstract
Background: The overdose crisis has generated innovative harm reduction and drug market monitoring strategies. In Toronto, Ontario, Canada, a multi-site drug checking service (DCS) pilot project was launched in October 2019. The project provides people who use drugs with information on the chemical composition of their substances, thereby increasing their capacity to make more informed decisions about their drug use and avoid overdose. DCS also provides real-time market monitoring to identify trends in the unregulated drug supply.

Methods: Sample data were obtained through analyses of drug and used drug administration equipment samples submitted anonymously and free of charge to DCS in downtown Toronto from October 10, 2019, to April 9, 2020, representing the first six months of DCS implementation. Analyses were conducted in clinical laboratories using liquid chromatography- and/or gas chromatography-mass spectrometry (LC–MS, GC–MS) techniques.

Results: Overall, 555 samples were submitted, with 49% (271) of samples that were found to contain high-potency opioids, of which 87% (235) also contained stimulants. Benzodiazepine-type drugs were found in 21% (116) of all samples, and synthetic cannabinoids in 1% (7) of all samples. Negative effects (including overdose, adverse health events, and extreme sedation) were reported for 11% (59) of samples submitted for analysis.

Conclusions: Toronto’s DCS identified a range of high-potency opioids with stimulants, benzodiazepine-type drugs, and a synthetic cannabinoid, AMB-FUBINACA. This information can inform a range of evidence-informed overdose prevention efforts.

Keywords: Drug overdose, Fentanyl, Etizolam, Flualprazolam, Synthetic cannabinoid
deaths of Ontarians aged 25–34 years is related to opioid overdose [4]. Moreover, the incidence of fatal overdose has increased in Ontario since the imposition of COVID-19 restrictions in March 2020 [5].

Public health alerts from Toronto Public Health exemplify patterns in adulteration of the unregulated street supply of substances in the downtown core over the course of the last decade. Between 2004 and 2013, Toronto Public Health reported a 41% increase in the reported number of fatal overdoses in Toronto, increasing from 146 to 206 [6]. From this time and until 2016, the unregulated drug supply was generally known to contain heroin by majority, and fentanyl as an emerging adulterant. Since 2016, the number of lives lost to fatal overdoses, and/or serious complications related to non-fatal overdoses, has only risen. Incidence of serious complications associated with opioid overdose has also increased by 67% from 2010 to 2019, 10% of whom died in the year following discharge [7]. It is now understood by service users and front-line support services that fentanyl and related high potency opioids are no longer a mere minor adulterant in the unregulated street supply of opioids but have now replaced what was largely a heroin market in 2016 as the current opioid majority and leads as the most commonly present opioid in accidental overdose deaths in Ontario [8, 9].

The dynamic uncertainty in the unregulated drug market has generated innovative harm reduction approaches in Canada, including the implementation of drug checking services (DCS) tailored for structurally vulnerable people who use drugs [10]. Originating in California amid the counterculture movement in the 1960s and early 1970s [11], and having later gained popularity in the 1990s in European nightlife and dance settings [12], DCS provide chemical analysis of substances to service users, helping them to make informed drug use decisions, while contributing data to drug market monitoring [13].

A multi-site DCS pilot was launched in Toronto, Ontario, Canada in October 2019 [14]. Intake sites are co-located with supervised consumption services at multiple harm reduction agencies. The project prioritizes providing structurally vulnerable (i.e., socially and economically marginalized) people who use drugs with information about the composition of their substances, thereby increasing their capacity to avoid overdose.

This report presents early trends of samples analyzed within the first six months of DCS implementation in Toronto (October 10, 2019–April 9, 2020). We sought to identify the prevalence of high-potency opioids in the unregulated drug supply and to identify noteworthy combinations thereof with stimulants, benzodiazepine-type drugs, and synthetic cannabinoids. We also present data on reported negative effects of samples (e.g., overdose).

Methods

In October 2019, Toronto’s Drug Checking Service launched DCS in downtown Toronto in collaboration with addiction and mental health and St. Michael’s Hospital, Toronto Public Health, and community partners. The protocol and rationale for the evaluation of Toronto’s DCS has previously been described [10]. In brief, we are evaluating the impact of Toronto’s DCS on overdose and related risk behaviors among service users and its capacity to identify trends in the chemical composition of Toronto’s unregulated drug supply. The results presented herein were obtained through chemical analyses of samples submitted anonymously and free of charge to DCS by a service user (i.e., the person who used or plans to use the substance, someone on their behalf, or other interested parties such as drug sellers), or a staff member at the harm reduction site on behalf of a service user. The submitted sample is assigned an anonymous and unique identifier code. Samples are analyzed at the Centre for Addiction and Mental Health or at St. Michael’s Hospital using liquid chromatography- and/or gas chromatography-mass spectrometry (LC–MS, GC–MS) techniques, which are the gold standards in forensic drug analysis [15].

The analytic results are supplemented by data from surveys administered during sample collection, which solicit information on the expected drug, whether drug administration equipment submitted for analysis was reused, and negative effects post-use. Upon submission, the individual is asked “What was this sample purchased as ()?,” which is reported as the drug that the individual expected to be present in the sample based on information provided at the time of purchase. The service user is also asked “Are you aware of this sample being associated with an overdose or adverse effect ()?”. An overdose is self-reported by the service user or by a staff member at the harm reduction site on behalf of the service user.

Results

Overall, 555 samples were submitted for analysis by DCS, among which 62% (n = 344) were substances (i.e., liquid, pill, powder) and 38% (n = 211) drug administration equipment (i.e., cooker, filter, or leftover liquid from
a used syringe), 10% (n = 21) of which were reportedly reused. The number of samples stratified by type and category of drug detected are presented in Fig. 1. Herein, data is presented by sample type, as drug administration equipment may contain remnants of chemicals from multiple uses and therefore may be less reliable than submitted substance samples with respect to adulteration. Nevertheless, both are important identifiers of what is currently circulating in the unregulated drug supply in downtown Toronto during the defined study period.

**Expected opioids and detected contents**

Of all samples submitted for analysis, 48% (n = 268) were expected to be the following opioids: carfentanil, fentanyl, or heroin. Fentanyl was expected most often, in 96% (n = 256) of the expected opioid samples. Figure 2 depicts the detected drugs in these expected opioid samples, including unexpected high-potency opioids, unexpected benzodiazepine-type drugs, and unexpected synthetic cannabinoids. Each sub-category of drugs detected are presented below in the context of being detected with high-potency opioids.

Furthermore, a sensitivity and specificity analysis with regards to concordance between expected and detected samples for all opioids, fentanyl, and heroin respectively are presented below in Table 1. Of note is the discordance evident for samples where heroin was detected by laboratory analysis but was not expected upon submission. Of these samples, 95% (n = 106) were expected to be fentanyl.

**Expected stimulants and detected contents**

Of all samples submitted for analysis, 20% (n = 110) were expected to be the following stimulants: amphetamine, cocaine, crack cocaine, or methamphetamine. Most samples were submitted as substances (n = 98). Note-worthy findings post-analysis include detection of fentanyl, hydromorphone, and oxycodone unexpectedly in 4% (n = 4) of expected stimulant samples. Fentanyl and hydromorphone were both detected unexpectedly in one expected crack cocaine sample submitted as drug administration equipment. Oxycodone was detected unexpectedly in a second expected crack cocaine sample submitted as a substance (note this sample did not contain cocaine—oxycodone was the sole compound found). Fentanyl was also detected unexpectedly in one expected methamphetamine sample submitted as a substance, which was reported as being associated with an overdose (note this sample did not contain methamphetamine—fentanyl was the sole compound found). These findings are summarized in Fig. 3.

![Graphical depiction of sample types stratified by category of drug detected (i.e., benzodiazepine, synthetic cannabinoid, or high-potency opioid) compared to total number of samples in that category (N = 555)](image)
Presence of stimulants with high-potency opioids

Of all samples submitted for analysis, 49% (n = 271) contained a high-potency opioid (i.e., fentanyl, fentanyl-related drugs, carfentanil). In 87% (n = 235) of these samples where a high-potency opioid was detected, one or more stimulants were found in combination, including caffeine, cocaine, or methamphetamine. Of this fraction of samples, a high-potency opioid (i.e., fentanyl, carfentanil) was expected in 210 samples, or 89%. The most frequent combinations detected were fentanyl with caffeine (n = 215), with cocaine (n = 57), and with methamphetamine (n = 43). Caffeine was the most commonly co-detected stimulant in 79% (n = 215). A stimulant was not expected in 97% of samples where a high potency opioid was detected with at least one stimulant. Drug administration equipment represents 67% (n = 181) of these samples.

Presence of benzodiazepine-type drugs

Of all samples submitted for analysis, 21% (n = 116) contained at least one benzodiazepine-type drug. Of these samples, 67% (n = 78) contained only one benzodiazepine and 33% (n = 38) contained two or more. Samples were submitted as a substance in 43% (n = 50), 4 of which were reported to be in pill form (e.g., described as “light green pill”, “white pill”, or “pill”). Other substance sample characteristics as described by the service user were “purple/blue” substances (n = 17), “clear” substance (n = 1), a “green powder” (n = 1), “pink to blue when cooked” (n = 1), and “yellow” (n = 1). The remaining samples were submitted as drug administration equipment (n = 66) whose visual characteristics were not described.

Majority of the detected benzodiazepines were found unexpectedly in submitted samples; only 13% (n = 15) were expected benzodiazepines. Fentanyl was expected
Table 1  Positive predictive values (PPV), negative predictive values (NPV), sensitivity and specificity are reported for concordance of expected and detected opioids, fentanyl, and heroin in samples submitted to DCS in Toronto, ON October 2019 to April 2020 (N = 555)

| Opioid           | Detected | Not detected | Total | PPV      | 94.08% (90.92, 96.18) |
|------------------|----------|--------------|-------|----------|-----------------------|
| Expected         | 270      | 17           | 287   | NPV      | 91.79% (88.2, 94.36)  |
| Not expected or unknown | 22      | 246          | 268   | Sensitivity | 92.47% (88.82, 95.22) |
| Total            | 292      | 263          | N = 555 | Specificity | 93.54% (89.85, 96.19) |

| Fentanyl         | Detected | Not detected | Total | PPV      | 93.31% (89.91, 95/62) |
|------------------|----------|--------------|-------|----------|----------------------|
| Expected         | 251      | 18           | 269   | NPV      | 93.01% (89.71, 95.31) |
| Not expected or unknown | 20      | 266          | 286   | Sensitivity | 92.62% (88.83, 95.43) |
| Total            | 271      | 284          | N = 555 | Specificity | 93.66% (90.17, 96.20) |

| Heroin           | Detected | Not detected | Total | PPV      | 100% |
|------------------|----------|--------------|-------|----------|------|
| Expected         | 8        | 0            | 8     | NPV      | 79.52% (78.74, 80.29) |
| Not expected     | 112      | 435          | 547   | Sensitivity | 66.7% (2.92, 12.71) |
| Total            | 120      | 435          | N = 555 | Specificity | 100% (99.16, 100) |

Fig. 3  A breakdown of unexpected fentanyl and related opioid drugs detected among the associated expected stimulant samples submitted to DCS (n = 110). *MDA: 3,4-Methylenedioxyamphetamine. **MDMA: 3,4-Methylenedioxymethamphetamine
in 80% (n = 93), and various other drugs in the remaining
7% (n = 8). Of the samples where fentanyl was expected
and benzodiazepines were detected, 65% (n = 60) were
submitted as drug administration equipment and 35%
(n = 33) as substances.

The primary benzodiazepine-type drugs detected were
etizolam (n = 95), flualprazolam (n = 46), alprazolam
(Xanax) (n = 9), flubromazolam (n = 4), and meclona-
zepam (n = 1). Samples containing benzodiazepine-type
drugs account for 41% (n = 24) of all samples associ-
ated with a negative effect during the study period, 67%
(n = 16) submitted as drug administration equipment and
33% (n = 8) as substance-type samples (i.e., an overdose
was implicated in 67% (n = 16) of the samples where a
benzodiazepine-type drug was detected 31% (n = 5) as
substance-type sample and 69% (n = 11) as drug admin-
istration equipment sample).

Presence of synthetic cannabinoids
Of all samples submitted for analysis, 1% (n = 7) con-
tained a synthetic cannabinoid, all of which were expected to be fentanyl. AMB-FUBINACA was the only
synthetic cannabinoid detected.

Negative effects
Survey responses indicate that 11% (n = 59) of all sam-
ple submitted for analysis were associated with nega-
tive effect. Of these samples, survey responses report
that: 63% (n = 37) were implicated in an overdose, 29%
(n = 17) were associated with adverse health events, and
8% (n = 5) were associated with extreme sedation.

Discussion
Across a six-month period in Toronto, a large proportion
of samples submitted to DCS contained high-potency
opioids presenting with unexpected stimulants. We also
detected various benzodiazepine-type drugs and a syn-
thetic cannabinoid, AMB-FUBINACA.

In the results presented herein, DCS provide further
evidence that the current opioid market in downtown
Toronto, Ontario, is saturated with fentanyl both appear-
ing as an adulterant but also as a predominant expected
substance upon sample submission. This prevalence of
fentanyl and related high-potency opioids is noteworthy
given that they carry increased risk for overdose. In
particular, when stimulants are adulterated with high-
potency opioids such as fentanyl and related drugs, the
risk for harms, including overdose, increases. This pat-
tern of adulteration has contributed to increasing poly-
drug overdose mortality [16]. Caffeine was the most
common stimulant co-presenting with high-potency opi-
oids, which is consistent with other settings [17].

The detection of various benzodiazepine-type drugs is
significant given the risk of overdose that they pre-
sent, especially when unexpected and combined with
opioids. Benzodiazepines elicit sedative and anxiolytic
effects that, when combined with other central nervous
system depressants, may amplify cardiovascular and res-
piratory depression and contribute to overdose severity
[18]. Compounding this issue is the lack of reliable and
effective antagonist therapies to reverse benzodiazepine
overdose outside of clinical settings [19]. Additionally,
increased use of benzodiazepines may increase tolerance
and the potential for withdrawal, especially if individuals
are not aware that they are using these substances. This
issue therefore demands greater urgency, as it appears
to be contributing to overdose mortality in Toronto and
elsewhere [20]. For instance, on February 26, 2020, a
notable spike in overdoses (16 in seven hours) in Toronto
was associated with drug samples containing large pro-
portions of flualprazolam along with fentanyl and caffe-
ine [21].

We also detected AMB-FUBINACA, an ultra-potent
synthetic cannabinoid that can be up to hundreds of
times more potent than D9-tetrahydrocannabinol [22].
Synthetic cannabinoid exposure may cause adverse
effects including neuropsychiatric, cardiovascular, and
renal impairment [23], but the effects of co-administra-
tion of AMB-FUBINACA and other central nervous sys-
tem depressants (e.g., benzodiazepines, opioids) remain
largely unknown. Antagonist therapies for synthetic can-
nabinoid intoxication have yet to be elucidated, and sup-
portive measures relevant to symptom management are
recommended (e.g., intravenous hydration, antipsychotic
in the cases of acute neuropsychiatric impairment, etc.)
[24]. It is therefore critical to share information on their
presentation in unregulated drug markets with people
who use drugs, harm reduction workers, and clinicians.

DCS serve as a tool to monitor and alert the public on
current drug supply trends and potential health harms.
In aggregate forms, this information can help front line
support (i.e., paramedics, service providers) to appropri-
ately respond to impending cases of overdose. For exam-
ple, if benzodiazepines or synthetic cannabinoids are
recognized as a common adulterant to opioid samples
(and thereby taken unknowingly), providing robust doses
of naloxone may not be sufficient in rousing the individ-
ual, and supportive measures related to benzodiazepine
or synthetic cannabinoid overdose may be applied [18,
24]. Beyond providing information to the public, when
results of the chemical analysis of submitted samples are
disseminated to service users themselves, they are bol-
stered with tailored harm reduction strategies relevant to
their personal substance use (e.g., protective behaviours
such as not using alone, carrying naloxone, using safe
consumption sites, using a smaller “test” dose, or discarding toxic substances). These personalized strategies can reduce harms associated with use of substances in discordance with what they were sold as or anticipated to be.

There are limitations to the capacity of Toronto’s DCS to provide a comprehensive analytical assessment of the unregulated drug supply. Inherent limitations of mass spectrometry analysis include accessibility, cost, destruction of the sample during analysis, contaminants obscuring data outputs, the speed at which results can be provided to service users, and the inability to detect certain non-drug compounds (e.g., metals, pesticides, inorganic salts, sugars) [15]. With regards to sample composition, the results may not represent the entire supply that samples are taken from, and reused drug administration equipment may contain substances from multiple uses and considered in interpretation of DCS data on co-presentation of samples of this type.

Conclusions
This report briefly highlights the presence of highly-potent substances and combinations thereof in Toronto’s unregulated drug market. Timely data and public health alerts are critical to inform people who may experience health harms from drug use and demonstrate the value of DCS for drug market monitoring. Examples of such alerts were issued by Toronto Public Health regarding noteworthy trends in Toronto’s unregulated drug supply [20].

However, DCS alone are insufficient to prevent overdose and mortality arising from an unregulated drug supply, especially among persons without access to medication-assisted treatment for drug dependence or other standard-dose regimens as a result of drug policies (e.g., drug criminalization) that amplify social marginalization [25]. Quantifying the persisting contaminated drug supply and addressing it with policy solutions such as safer supply or other standard-dose modalities is therefore urgently needed [26].

As the global COVID-19 pandemic continues, drug trafficking patterns and supply are likely to remain dynamic [22]. This increases the need to sustain and expand DCS to prevent overdose and to monitor drug market fluctuations.

Acknowledgements
We wish to acknowledge our partnering harm reduction agencies—Parkdale Queen West Community Health Centre (Queen West site), South Riverdale Community Health Centre, and The Works at Toronto Public Health, and partnering clinical laboratories (Centre for Addiction and Mental Health and St. Michael’s Hospital). We thank the members of the Community Advisory Board for Toronto’s DCS for their guidance. We also thank those who trusted us with their samples and provided feedback on the service. Toronto’s DCS is supported by an operating grant from Health Canada’s Substance Use and Addictions Program and the St. Michael’s Hospital Foundation. Dan Werb is supported by the Canadian Institutes of Health Research via a New Investigator Award, and the Ontario Ministry of Research, Innovation and Science via an Early Researcher Award. Nazlee Maghsoudi is supported by a CIHR Vanier Canada Graduate Scholarship. We acknowledge that the land on which we conduct our research is the traditional territory of many nations including the Mississaugas of the Credit, the Anishinabe, the Chippewa, the Haundenosaunee, and the Wendat peoples, now also home to many diverse First Nations, Inuit, and Métis peoples.

Authors’ contributions
Laboratory analysis data was generated by CS, DRB, EW, and ME. DW, NM, and KM conceptualized the paper. KMS drafted the manuscript and figures. All authors reviewed and provided substantive input on the manuscript. All authors read and approved the final manuscript.

Funding
Toronto’s Drug Checking Service is supported by an operating grant from Health Canada’s Substance Use and Addictions Program (Award #1718-HQ-000027, Recipient: Dan Werb, PhD) and the St. Michael’s Hospital Foundation. Dan Werb is supported by the Canadian Institutes of Health Research via a New Investigator Award, and the Ontario Ministry of Research, Innovation and Science via an Early Researcher Award. Nazlee Maghsoudi is supported by a CIHR Vanier Canada Graduate Scholarship.

Availability of data and materials
A selection of the data presented herein is available online at: https://drugchecking.cdpe.org/.

Declarations
Ethics approval and consent to participate
Research Ethics Board approval has been obtained for this research study from Unity Health Toronto, Toronto Public Health, Centre for Addiction and Mental Health, and University of Toronto.

Consent for publication
While informed consent is obtained from participants for this study, the present manuscript does not publish any identifiable personal data or images.

Competing interests
The authors declare that they have no competing interests.

Author details
1Centre On Drug Policy Evaluation, c/o Li Ka Shing Knowledge Institute of St. Michael’s Hospital, 30 Bond Street, Toronto, ON M5B1W8, Canada. 2Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada. 3Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. 4Clinical Laboratory and Diagnostic Services, Centre for Addiction and Mental Health, Toronto, ON, Canada. 5Department of Laboratory Medicine, St. Michael’s Hospital, Toronto, ON, Canada. 6Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 7Toronto Public Health, Toronto, ON, Canada. 8Toronto Harm Reduction Alliance, Toronto, ON, Canada. 9Provincial System Support Program, Centre for Addiction and Mental Health, Toronto, ON, Canada. 10Division of Infectious Diseases and Global Public Health, University of California San Diego School of Medicine, La Jolla, CA, USA.

Received: 6 July 2021 Accepted: 15 December 2021
Published online: 11 January 2022

References
1. U. S. Drug Enforcement Administration, Diversion Control Division. National Forensic Laboratory Information System:NFLIS-Drug 2019 Midyear Report. Springfield, VA. 2020. https://www.nflis.deadiversion.usdoj.gov/nflisdata/docs/NFLIS-DRUG_2019_Annual_Report.pdf?search=2019%20Midyear
2. Payer DE, Young MM, Maloney-Hall B, Mill C, Leclerc P, Buxton J, the Canadian Community Epidemiology Network on Drug Use, the National Drug Checking Working Group. Adulterants, contaminants and co-occurring substances in drugs on the illegal market in Canada: an analysis of data from drug seizures, drug checking and urine toxicology. Ottawa: Canadian Centre on Substance Use and Addiction. 2020. https://www.ccsa.ca/sites/default/files/2020-04/CCSA-CCENDU-Adulterants-Contaminants-Co-occurring-Substances-in-Drugs-Canada-Report-2020-en.pdf.

3. Public Health Agency of Canada; Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioids and stimulant-related Harms in Canada. Ottawa: Government of Canada Health Infobase. 2020. https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants.

4. Gomes T, Greaves S, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. Measuring the burden of opioid-related mortality in Ontario, Canada. J Addict Med. 2018;12(5):418.

5. Gomes T, Kitchen SA, Murray R. Measuring the burden of opioid-related mortality in Ontario, Canada, during the COVID-19 pandemic. JAMA Netw Open. 2021;4(5):e2112865.

6. Overdose in Toronto: Trends, prevention and response. City of Toronto. Toronto Public Health; 2021. https://www.toronto.ca/legdocs/mmsi/2015/hl/bgrd/backgroundfile-83429.pdf.

7. Kitchen SA, McCormack D, Werb D, Caudarella A, Martins D, Matheson FJ, Gomes T. Trends and outcomes of serious complications associated with non-fatal opioid overdoses in Ontario, Canada. Drug Alcohol Dependence. 2021;225:108830.

8. Opoid mortality surveillance report—Public Health Ontario. 2019. https://www.publichealthontario.ca/-/media/documents/O/2019/opoid-mortality-surveillance-report.pdf.

9. McDonald K, Maghsoudi N, Thompson H, Werb D. What’s in Toronto’s drug supply? Toronto: Centre on Drug Policy Evaluation; 2020. https://drugchecking.cdpe.org/.

10. House of Commons of Canada, Standing Committee on Health. Report and recommendations on the opioid crisis in Canada. Ottawa: Government of Canada Publications, 2016. https://publications.gc.ca/collections/collection_2016/parl/xgc2-1/XGc2-1-1-421-6-eng.pdf.

11. Renfroe CL. MDMA on the street: analysis Anonymous®. J Psychoact Drugs. 1986;18(4):363–9.

12. Smit-Rigter L, Van der Gouwe D. The Drugs Information and Monitoring System (DIMS). Factsheet on drug checking in the Netherlands. Utrecht: Trimbos Institute; 2019.

13. Ontario Agency for Health Protection and Promotion (Public Health Ontario), Leece P. Evidence brief: evidence on drug checking services as a harm reduction intervention. Toronto: Queen’s Printer for Ontario; 2017. https://www.publichealthontario.ca/-/media/documents/E/2017/eb-drug-checking.pdf.

14. Maghsoudi N, McDonald K, Stefan C, Beriault DR, Mason K, Barnaby L, Altenberg J, MacDonald RD, Caldwell J, Nisenbaum R, Leece P. Evaluating networked drug checking services in Toronto, Ontario: study protocol and rationale. Harm Reduct J. 2020;17(1):1.

15. Harper L, Powell J, Pijl EM. An overview of forensic: drug testing methods and their suitability for harm reduction point-of-care services. Harm Reduct J. 2017;14(1):1–3.

16. Ciccarone D. The rise of illicit fentanyl, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344–50.

17. Tupper KW, McCrae K, Garber I, Lysyshyn M, Wood E. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting. Drug Alcohol Depend. 2018;190:242–5.

18. Guina J, Merrill B. Benzodiazepines I: upping the care on downers: the evidence of risks, benefits and alternatives. J Clin Med. 2018;7(2):17.

19. Kang M, Galuska MA, Ghassemzadeh S. Benzodiazepine toxicity. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2019. https://www.ncbi.nlm.nih.gov/books/NBK482238/.

20. Gervykyan J, Kinyua J, Pearing S, Rodda LN. A case series of Etizolam in opioid-related deaths. J Anal Toxicol. 2021. https://doi.org/10.1093/jat/bkaa146.

21. Toronto Public Health. Increase in overdoses observed at The Works on February 26, 2020. Toronto: Toronto Public Health; 2020. https://www.toronto.ca/wp-content/uploads/2020/02/9477-Alert_Increase-in-Overdoses-on-February-26_2020.pdf.

22. Riederer AM, Campleman SL, Carlson RG, Boyer EW, Manini AF, Wax PM, Brent JA. Acute poisonings from synthetic cannabinoids—50 US

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.